SG11201909041SA - Anti-pd-l1 antibody and use thereof - Google Patents
Anti-pd-l1 antibody and use thereofInfo
- Publication number
- SG11201909041SA SG11201909041SA SG11201909041SA SG11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA SG 11201909041S A SG11201909041S A SG 11201909041SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- moscow
- pct
- antibodies
- fully human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2017028206 | 2017-04-18 | ||
| PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909041SA true SG11201909041SA (en) | 2019-11-28 |
Family
ID=63856823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909041S SG11201909041SA (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (https=) |
| EP (1) | EP3612565A4 (https=) |
| JP (2) | JP2020517239A (https=) |
| KR (1) | KR102323960B1 (https=) |
| CN (1) | CN110856446A (https=) |
| AU (1) | AU2018256392B2 (https=) |
| BR (1) | BR112019021828B1 (https=) |
| CA (1) | CA3059447A1 (https=) |
| CL (1) | CL2019002953A1 (https=) |
| CO (1) | CO2019012118A2 (https=) |
| EA (1) | EA201900443A1 (https=) |
| MA (1) | MA50038A (https=) |
| MX (1) | MX2019012461A (https=) |
| MY (1) | MY199319A (https=) |
| PH (1) | PH12019502302A1 (https=) |
| SG (1) | SG11201909041SA (https=) |
| WO (1) | WO2018195226A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| CA3120096A1 (en) | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
| CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| CN113677709B (zh) * | 2019-04-11 | 2024-08-23 | 斯克里普斯抗体研究所 | 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途 |
| EP3833691B1 (en) * | 2019-04-26 | 2024-09-25 | I-Mab Biopharma Co., Ltd. | Human pd-l1 antibodies |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| CN116178545B (zh) * | 2021-09-24 | 2025-09-12 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| AU2009333580B2 (en) * | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2015061668A1 (en) * | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| KR20220062143A (ko) * | 2014-01-06 | 2022-05-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
| CA2940242C (en) * | 2014-02-20 | 2026-01-13 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN117088979A (zh) * | 2016-10-30 | 2023-11-21 | 上海复宏汉霖生物技术股份有限公司 | 抗-pd-l1抗体及变异体 |
-
2018
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active Active
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt not_active IP Right Cessation
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en not_active Withdrawn
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3612565A4 (en) | 2021-06-16 |
| EA201900443A1 (ru) | 2020-03-06 |
| MA50038A (fr) | 2020-07-08 |
| MX2019012461A (es) | 2019-12-11 |
| PH12019502302A1 (en) | 2020-09-21 |
| JP2020517239A (ja) | 2020-06-18 |
| KR20190141169A (ko) | 2019-12-23 |
| JP2023025003A (ja) | 2023-02-21 |
| BR112019021828B1 (pt) | 2022-09-20 |
| MY199319A (en) | 2023-10-24 |
| KR102323960B1 (ko) | 2021-11-10 |
| AU2018256392B2 (en) | 2024-05-16 |
| CO2019012118A2 (es) | 2020-04-01 |
| BR112019021828A2 (pt) | 2020-03-24 |
| WO2018195226A1 (en) | 2018-10-25 |
| CA3059447A1 (en) | 2018-10-25 |
| CN110856446A (zh) | 2020-02-28 |
| AU2018256392A1 (en) | 2019-10-17 |
| CL2019002953A1 (es) | 2020-01-10 |
| US20210115143A1 (en) | 2021-04-22 |
| EP3612565A1 (en) | 2020-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909041SA (en) | Anti-pd-l1 antibody and use thereof | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
| SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |